Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 11/20 | 0.88 |
| ▸ | ECE1 | P42892 | 1/20 | 0.88 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.88 |
| ▸ | CCKBR | P32239 | 1/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.80 |
| ▸ | CCKAR | P32238 | 1/20 | 0.75 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.75 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.75 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462206 | 0.98 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29360422 | 0.98 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Glp-1 SCHEMBL29353361 | 0.98 | GLP1R (0.89) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL31060658 | 0.98 | GLP1R (0.89) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Oxyntomodulin SCHEMBL29349603 | 0.94 | GLP1R (0.84) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Liraglutide SCHEMBL20511941 | 0.94 | GLP1R (1.00) | GLP1RECE1MUS81CCKAR | |
| SCHEMBL29358622 | 0.94 | GLP1R (0.82) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL30658278 | 0.94 | GLP1R (0.77) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29498823 | 0.94 | GLP1R (0.77) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29634677 | 0.94 | GLP1R (0.77) | GLP1RECE1MUS81CCKBRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605344-B2 | Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| EP-3034090-B1 | STABLE INSULIN SECRETAGOGUE PEPTIDE HYDRO-INJECTION PHARMACEUTICAL COMPOSITION | SHANGHAI BENEMAE PHARMACEUTICAL CORP (CN) | 2025-05-14 | — | — | EP | claimed |
| EP-4061399-B1 | INSULINOTROPIC AND GLUCAGONOTROPIC EFFECTS OF BETA-LACTOGLOBULIN | ARLA FOODS AMBA (DK) | 2024-02-14 | — | — | EP | claimed |
| EP-3628101-B1 | METHOD AND SYSTEM FOR MANAGING LIFESTYLE AND HEALTH INTERVENTIONS | BETTER THERAPEUTICS LLC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-4106743-A1 | AZELAIC ACID ESTERS IN THE TREATMENT OR PREVENTION OF DYSLIPIDEMIA AND ASSOCIATED CONDITIONS | New Frontier Labs, LLC (US) | 2022-12-28 | — | — | EP | claimed |
| EP-4085907-A1 | DIETHYL AZELATE IN THE TREATMENT OF TYPE 2 DIABETES | New Frontier Labs, LLC (US) | 2022-11-09 | — | — | EP | claimed |
| US-20220102006-A1 | MACHINE LEARNING PREDICTION OF THERAPY RESPONSE | OPENDNA LTD. (IL) | 2022-03-31 | — | — | US | claimed |
| EP-3968339-A1 | MACHINE LEARNING PREDICTION OF THERAPY RESPONSE | Opendna Ltd. (IL) | 2022-03-16 | — | — | EP | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3634474-B1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL EUROPE GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090418-A1 | ULTRA-EFFICIENT RNA SWITCHES AND RELATED EXPRESSION SYSTEMS | UNIVERSITY OF MASSACHUSETTS (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260119012-A1 | METHOD AND SYSTEM FOR MANAGING LIFESTYLE AND HEALTH INTERVENTIONS | Click Therapeutics, Inc. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12613622-B1 | Method and system for managing lifestyle and health interventions | Click Therapeutics, Inc. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260110013-A1 | PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN | AMGEN INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-11254963-B2 | Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11247001-B2 | Delivery device with cantilever structure and associated method of use | De Motu Cordis Pty Ltd (AU) | 2022-02-15 | — | — | US | disclosed |
| US-11248037-B2 | Multivalent heteromultimer scaffold design and constructs | ZYMEWORKS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| US-20220040464-A1 | NANOPATTERNED MEDICAL DEVICE WITH ENHANCED CELLULAR INTERACTION | SOFUSA HOLDINGS LLC | 2022-02-10 | — | — | US | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236079-B2 | Morpholine derivates as inhibitors of Vps34 | NEUROPORE THERAPIES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12613622-B1 | Method and system for managing lifestyle and health interventions | LPL, LIPC, STAT6 | GLP1R 33/4885ECE1 2676/4885MUS81 1729/4885 |
| US-12605344-B2 | Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents | SPPL2B, SPPL2A, YWHAZ | GLP1R 197/4885ECE1 4152/4885MUS81 4675/4885 |
| US-20260119012-A1 | METHOD AND SYSTEM FOR MANAGING LIFESTYLE AND HEALTH INTERVENTIONS | LPL, LIPC, STAT6 | GLP1R 33/4885ECE1 2676/4885MUS81 1729/4885 |
| US-11236079-B2 | Morpholine derivates as inhibitors of Vps34 | VPS35, TFEB, VPS4B | GLP1R 4017/4885ECE1 3894/4885MUS81 4617/4885 |
| US-20260110013-A1 | PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN | FUCA2, FUCA1, GOLIM4 | GLP1R 3506/4885ECE1 4758/4885MUS81 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.